A multicentered prospective study of the role of contrast enhanced ultrasound assisted by Kupffer cell specially-uptaken contrast in surgical treatment of hepatic malignancies

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065890

Enrollment

Unknown

Registered

2022-11-17

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic cell carcinoma and liver metastasis

Interventions

study group:RFA, local and segmental hepatectomy assisted by CEUS with Kupffer cell specially-uptaken contrast

Control group:Conventional surgical treatment without this technology

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Liver malignancies (HCC and liver metastasis) that are subject to radiofrequency ablation, local hepatectomy or segmental hepatectomy; 2. The diameter of the largest lesion to be ablated is less than 5cm; 3. Preoperative imaging examination shows that the lesions are visible and countable; 4. No history of contrast agent allergy, egg allergy, and no surgical contraindication; 5. Subjects are willing to receive regular follow-up, with complete data, self-control ability, understanding and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Multi-segmental hepatectomy, half or extended-half hepatectomy; 2. Use other contrast-enhanced ultrasound techniques during operation; 3. Non surgical treatment, such as interventional therapy, targeted therapy, radiotherapy, etc.

Design outcomes

Primary

Measure	Time frame
Complete remission rate of the lesion;	—

Countries

China

Contacts

Public ContactJingyong Xu

Beijing Hospital

xujingyong@bjhmoh.cn+86 13810351797

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026